Clinical Comparison
Modafinil vs Vyvanse
Two completely different mechanisms, two completely different risk profiles. After testing modafinil since 2014, here is the evidence-backed answer to which one fits your situation.
The Bottom Line
For cognitive enhancement in healthy adults: modafinil wins decisively. It provides sustained focus with minimal abuse potential, no rapid tolerance, and far lower cardiovascular risk. For diagnosed ADHD with a prescribing physician: Vyvanse is FDA-approved and generally more effective, but carries amphetamine-class risks that modafinil does not. Choose based on clinical context, not which one sounds stronger.
Is modafinil like Vyvanse?
No. They are fundamentally different drug classes. Modafinil (Provigil, generics Modalert and Modvigil) selectively inhibits dopamine reuptake in wakefulness centres without causing euphoria or significant addiction risk. It is Schedule IV. Vyvanse (lisdexamfetamine) is a prodrug that converts to dextroamphetamine in the bloodstream, flooding the reward system with dopamine. It is Schedule II with high abuse potential.
Key differences at a glance
Modafinil (Provigil)
Class: Eugeroic / wakefulness promoter
Generics: Modalert (Sun Pharma), Modvigil (HAB Pharma)
FDA approved: December 1998 (narcolepsy, sleep apnea, shift work)
DEA Schedule: IV, low abuse potential
Mechanism: Selective DAT inhibition in wakefulness circuits
Tolerance: Minimal, efficacy sustained over 12+ months
Withdrawal: 1 to 2 days mild fatigue
Vyvanse (Lisdexamfetamine)
Class: Amphetamine prodrug
Generic: Lisdexamfetamine (Teva, available since Aug 2023)
FDA approved: February 2007 (ADHD, binge eating disorder)
DEA Schedule: II, high abuse potential
Mechanism: Prodrug converts to dextroamphetamine, floods dopamine + norepinephrine
Tolerance: Rapid, 2 to 4 weeks typical
Withdrawal: 7 to 14 days depression + fatigue
Prescription logistics matter: Vyvanse is Schedule II. No refills, no phone-in, monthly paper prescription required. Modafinil is Schedule IV. Refills permitted, phone prescriptions allowed, substantially less monitoring burden.
Clinical comparison: modafinil vs Vyvanse
Data sourced from FDA prescribing information, peer-reviewed pharmacokinetic studies, and clinical trial reports.[1][2]
Sources: FDA prescribing information (modafinil NDA 021447, Vyvanse NDA 021977); Taylor and Russo 2000; peer-reviewed pharmacokinetic literature.
How they work: mechanism determines everything
Modafinil: selective DAT inhibition
Modafinil inhibits the dopamine transporter (DAT), blocking reuptake selectively in the hypothalamus and thalamus. These are the brain's wakefulness centres. It also modulates histamine and orexin pathways that regulate circadian alertness.
The result is enhanced dopamine signalling in sleep-wake circuits without flooding the reward system. This explains the absence of euphoria, the low abuse potential, and why receptor downregulation rarely occurs.
Half-life: 12 to 15 hours. The clinical effect window is typically 10 to 12 hours for most users.[1]
Vyvanse: the prodrug mechanism
Vyvanse is lisdexamfetamine. Your body must cleave a lysine amino acid from the molecule before releasing active dextroamphetamine. This enzymatic conversion in red blood cells is why Vyvanse has a smoother onset than immediate-release amphetamines and why it cannot be crushed or snorted for abuse.
Once converted, dextroamphetamine forces presynaptic neurons to release massive stores of dopamine and norepinephrine and blocks reuptake transporters simultaneously. This dual action floods the entire reward system, not just wakefulness circuits.
Your brain responds by downregulating dopamine receptors within weeks. This is why tolerance is pharmacologically inevitable with daily amphetamine use, and why stopping feels so bad.
Side effect profiles: where safety separates
Modafinil: common side effects
Rare: Stevens-Johnson syndrome (genetic predisposition HLA-B*1502), reduced oral contraceptive efficacy (enzyme induction)[1]
Vyvanse: common side effects (10%+ of users)
Serious: Cardiovascular events in at-risk individuals, psychosis or mania induction, psychological dependence[2]
Medical monitoring difference: Modafinil typically requires baseline assessment and periodic review. Vyvanse (Schedule II) requires monthly visits, cardiovascular monitoring, blood pressure tracking, and careful psychiatric screening.
For ADHD: the honest evidence-based answer
What the research shows
Taylor and Russo (2000) found modafinil comparable to dextroamphetamine for ADHD symptom control (p less than .001), with a cleaner side effect profile.[3]
However, a 2023 meta-analysis found amphetamine-class drugs, including Vyvanse, generally superior to modafinil for ADHD overall, particularly for hyperactivity-dominant presentations. Modafinil performs best for inattentive-type ADHD with significant executive function deficits.
Clinical decision framework
Severe ADHD, hyperactive type: Vyvanse likely more effective. Discuss with psychiatrist.
Inattentive-type ADHD: Modafinil is a viable first-line alternative with fewer risks.
Substance abuse history: Modafinil strongly preferred. Schedule IV vs II matters enormously.
Cardiovascular or anxiety concerns: Modafinil preferred. Vyvanse frequently worsens both.
The bottom line for ADHD: Both work. Vyvanse is statistically stronger for severe ADHD overall. But "statistically stronger" comes with Schedule II restrictions, rapid tolerance, cardiovascular risk, and significant withdrawal. The risk-benefit calculation is highly individual.
Tolerance and dependence: the long-term reality
Vyvanse: the tolerance trap
Amphetamine tolerance is pharmacologically predictable with daily use. Within 2 to 4 weeks, most patients notice diminished effects at their prescribed dose.
This creates three outcomes: dose escalation (accelerates tolerance and cardiovascular risk), tolerance breaks (7 to 14 days of depression every few months), or diminished returns (medication that no longer works optimally).
Modafinil: sustained efficacy
Studies on shift workers using modafinil daily for 12+ months report minimal tolerance development. The 200mg dose typically remains effective without escalation.
Many professionals use a 2 to 3 days per week protocol, maintaining full efficacy indefinitely. A flexibility that amphetamines simply cannot offer without withdrawal management.
Cost comparison: updated 2026
Modafinil pricing (2026)
US Rx generic: $30 to $80 per month (insurance dependent)
International generic Modalert 200 (Sun Pharma): from $0.89 per pill via verified vendors
International generic Modvigil 200 (HAB Pharma): comparable pricing
2 to 3 days per week dosing: brings monthly cost to $10 to $25 at international pricing
Vyvanse pricing (2026)
Brand Vyvanse: $350 to $500 per month without insurance
Generic lisdexamfetamine (Teva, patent expired Aug 2023): $60 to $90 per month with discount programs
Monthly psychiatrist visit (Schedule II requirement): $100 to $300 additional
Tolerance-driven dose escalation adds cost over time
Who should choose which
Choose modafinil if
Vyvanse may be appropriate if
Where to buy modafinil online
Every vendor below stocks pharmaceutical-grade generics made under WHO-GMP standards. For full vendor vetting, see the safe buying guide. For a second opinion, see our full BuyModa review.
Frequently asked questions
Can you take modafinil and Vyvanse together?
This combination is occasionally used under close psychiatric supervision for treatment-resistant ADHD. However, combining them significantly elevates cardiovascular risk, increases CNS stimulation, and heightens anxiety potential. Never combine them without a prescribing physician who knows your complete medication list.
Which is better for ADHD: modafinil or Vyvanse?
Vyvanse is FDA-approved for ADHD and is generally more effective for severe presentations. Taylor and Russo (2000) showed modafinil is statistically comparable to dextroamphetamine for ADHD symptom control, with a cleaner side effect profile.[3] For inattentive-type ADHD, the gap narrows considerably. Work with your psychiatrist to determine what fits your presentation.
Is modafinil a good replacement for Vyvanse?
For cognitive enhancement in healthy adults: yes, decisively. For mild to moderate ADHD: often yes, especially when stimulant side effects are problematic. For severe ADHD: probably not. The right answer depends entirely on why you are considering the switch.
How do I switch from Vyvanse to modafinil?
This requires physician supervision. Vyvanse discontinuation after extended daily use typically requires a gradual taper (10 to 25mg dose reductions weekly) to minimise withdrawal. Cold-stopping Schedule II amphetamines causes severe rebound depression that can last 7 to 14 days. See our modafinil dosage guide for titration information.
Which is cheaper: modafinil or Vyvanse in 2026?
Modafinil is substantially cheaper at every level. Generic lisdexamfetamine (available since Teva's patent expired August 2023) runs $60 to $90 per month. US-prescribed generic modafinil is $30 to $80. International generic modafinil (Modalert, Modvigil) from verified vendors runs $0.89 to $1.49 per 200mg tablet.
Is modafinil "just weak Vyvanse"?
No. Modafinil is not a weaker amphetamine. It is a completely different drug class operating through DAT inhibition in wakefulness-specific circuits, not amphetamine-style monoamine release across the whole brain. The experience is qualitatively different, not quantitatively lesser.
What about the Vyvanse shortage: is modafinil a viable bridge?
Supply chain disruptions caused widespread Vyvanse shortages throughout 2024 and into 2025. Modafinil has been used as a short-term bridge option under prescriber guidance. It does not replicate Vyvanse's full effect for hyperactive ADHD, but can maintain productive functioning through a shortage period. Discuss temporary modafinil use with your prescribing psychiatrist.
References
- U.S. FDA. PROVIGIL (modafinil) prescribing information. Cephalon/Teva. NDA 021447. FDA.gov
- U.S. FDA. VYVANSE (lisdexamfetamine) prescribing information. Shire/Takeda. NDA 021977. FDA.gov
- Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of ADHD in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311-320. PubMed
- Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 2015. PubMed
- National Institute on Drug Abuse. Prescription Stimulants DrugFacts, 2024. NIDA.gov
Ready to try modafinil?
After testing vendors since 2014, we only list suppliers that pass purity verification, ship reliably, and honour their guarantee. WHO-GMP certified generics at a fraction of the price.
Check Verified Vendors